Environmental, Social and Governance

View of the sky through trees in a forest (by Ben Ostrower/Unsplash)

Environmental, Social and Governance

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen. These standards encompass environmental, social and corporate governance (ESG) topics and form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Corporate Reporting, including our annual Novartis in Society report.

Building Trust with Society and Culture Transformation

Building Trust and Reputation with Society

Building trust with Society is a key priority and is supported by four pillars which are being regularly tracked.

  • A woman dancing

    Ethical Standards

  • Pricing and Access

  • An elderly asian woman talks to her doctor

    Global Health

  • Responsible Citizenship

Our Culture Transformation

We believe embracing an inspired, curious and unbossed culture drives performance.

  • People in the park

    People

  • Novartis associates walk on campus

    Leadership

  • Novartis Campus Visitor Center

    Performance Management

Environmental Sustainability

Novartis strives to make efficient use of natural resources and to minimize the environmental impact of our activities and products. We have clear strategies and ambitious targets in the areas of climate change, water consumption and waste management. Our ambition is to be a catalyst for positive change and a leader in environmental sustainability.

Learn More

Social Topics

Access to medicine

Novartis is committed to bringing more of our medicines to more people, no matter where they are. For all our new medicines, we will systematically integrate access strategies in how we research, develop and deliver globally.This will be a key measure of success for our leaders and employees.

Learn More

Human Rights

Novartis conducts business in a manner that respects the rights and dignity of all people. We respect and support the protection of human rights, as enshrined in the United Nations (UN) Universal Declaration of Human Rights. We are also committed to core labor standards set out by the International Labor Organization (ILO) and are a signatory of the UN Global Compact.

Novartis Human Rights Guideline (PDF 0.1 MB)

Responsible Supply Chain

Novartis engages with an extensive network of suppliers worldwide and their contributions are crucial to our success. With such global reach, ensuring that our goods and services are ethically sourced is paramount.

Learn More

Diversity & Inclusion (D&I)

D&I is a fundamental part of our culture aspiration to be curious, inspired and unbossed. Novartis embraces diverse perspectives and values inclusive behavior. We are passionate about D&I because it fuels innovation, drives engagement and attracts talent.

Learn More

Novartis also has clear commitments to many other social topics including the living wage, quality of products and use of animals in research.

Corporate Governance

Novartis is fully committed to good corporate governance. Our corporate governance framework consists of rules that support sustainable financial performance and long-term value creation for our shareholders, and that are aligned with our values and behaviors.

Learn More

Novartis in Society Report

Transparent reporting has been a central part of our commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report, which provides in-depth information about ESG topics, is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

Learn more

We aim to meet the needs and expectations of our stakeholders by offering easy access to key data on important areas of our business, including payments to healthcare professionals and organizations and patient groups, clinical trial results and our US business